Latest Breaking News On - கண் ஆலோசகர்கள் - Page 1 : comparemela.com

Unity Biotechnology CEO Anirvan Ghosh, Ph.D. (Unity) Nearly a year after dropping its lead program and sinking its stock, Unity Biotechnology appears to be coming back on track with positive data in its phase 1 study in patients with advanced vascular eye disease.  The anti-aging biotech said Tuesday its small-molecule inhibitor of Bcl-xL, a senolytic therapeutic, was well tolerated in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Unity shares were up about 9% in early trading Tuesday morning. The study of UBX1325 was conducted in patients for whom anti–vascular endothelial growth factor (anti-VEGF) therapy was not considered to be beneficial anymore. Anti-VEGF treatments include Roche s Lucentis, Regeneron s Eylea, Novartis Beovu and Roche s Avastin.

United statesRoche lucentisRoche avastinAnirvan ghoshNovarti beovuJeffrey heierRegeneron eyleaRetina research at ophthalmic consultants of bostonVitreoretinal serviceUnity biotechnologyRetina researchOphthalmic consultantsஒன்றுபட்டது மாநிலங்களில்ஜெஃப்ரி ஹேஎர்விழித்திரை ஆராய்ச்சி இல் கண் ஆலோசகர்கள் ஆஃப் போஸ்டன்விதிறெோரேதினாள் சேவை